Back to Search
Start Over
Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma.
- Source :
-
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Mar 01; Vol. 27 (5), pp. 1287-1295. Date of Electronic Publication: 2020 Nov 10. - Publication Year :
- 2021
-
Abstract
- Purpose: In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma.<br />Patients and Methods: Twenty-four patients in two cohorts were enrolled and received ipilimumab at 3 mg/kg every 3 weeks for four doses in conjunction with radiation; median dose was 4,000 cGy (interquartile range, 3,550-4,800 cGy). Patients in cohort 1 were treated adjuvantly; patients in cohort 2 were treated either neoadjuvantly or as definitive therapy.<br />Results: Adverse event profiles were consistent with those previously reported with checkpoint inhibition and radiation. For the neoadjuvant/definitive cohort, the objective response rate was 64% (80% confidence interval, 40%-83%), with 4 of 10 evaluable patients achieving a radiographic complete response. An additional 3 patients in this cohort had a partial response and went on to surgical resection. With 2 years of follow-up, the 6-, 12-, and 24-month relapse-free survival for the adjuvant cohort was 85%, 69%, and 62%, respectively. At 2 years, all patients in the neoadjuvant/definitive cohort and 10/13 patients in the adjuvant cohort were still alive. Correlative studies suggested that response in some patients were associated with specific CD4 <superscript>+</superscript> T-cell subsets.<br />Conclusions: Overall, concurrent administration of ipilimumab and radiation was feasible, and resulted in a high response rate, converting some patients with unresectable disease into surgical candidates. Additional studies to investigate the combination of radiation and checkpoint inhibitor therapy are warranted.<br /> (©2020 American Association for Cancer Research.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological therapeutic use
Feasibility Studies
Female
Follow-Up Studies
Humans
Male
Melanoma pathology
Middle Aged
Neoplasm Recurrence, Local pathology
Prognosis
Prospective Studies
Radiotherapy Dosage
Survival Rate
Young Adult
Chemoradiotherapy, Adjuvant mortality
Ipilimumab therapeutic use
Melanoma therapy
Neoadjuvant Therapy mortality
Neoplasm Recurrence, Local therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1557-3265
- Volume :
- 27
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publication Type :
- Academic Journal
- Accession number :
- 33172894
- Full Text :
- https://doi.org/10.1158/1078-0432.CCR-20-2452